Gene Editing's Safety Test Runs on Children
Twelve Months of Silence
HuidaGene Therapeutics, a Shanghai gene-editing biotech, told the public on August 5 that a boy enrolled in its Duchenne muscular dystrophy trial died in August 2025, a year earlier, after a high dose of its CRISPR-based therapy HG302 triggered a severe immune reaction and acute respiratory distress syndrome. The company did not disclose the death voluntarily. STAT News forced it out after a months-long investigation. The trial ran as an 'investigator-initiated trial,' a Chinese track open since 2015 that lets a hospital, here Shanghai Children's Medical Center, launch and run a first-in-human gene therapy study without sign-off from the national drug regulator. STAT's review found the study had no independent data monitoring committee, the outside panel whose job is to unblind a trial and halt it when harm outweighs benefit, and no listing in China's national trial registry, so no external body was positioned to catch the death or force an accounting. HuidaGene's CEO and chief technology officer both left the company in the fifteen months between the first conference data on HG302 and this week's disclosure. Three boys, four to eight years old, remain enrolled in HG302's four-patient roster. Their families are deciding right now whether to continue, on a year-old fact they only just received.
Same Biology, Two Regimes
Duchenne muscular dystrophy affects nearly every muscle in the body at once, caused by a missing dystrophin gene, and that scale is what makes its gene therapies dangerous in a specific way. To edit or replace a gene in a boy's diaphragm, heart and every limb, a treatment has to go in systemically, at a dose far higher than a therapy aimed at a single organ needs. Sarepta's Elevidys, an AAV vector carrying a shortened dystrophin gene, and HuidaGene's HG302, a CRISPR gene-editing payload, are different technologies solving the same delivery problem the same way: flood the bloodstream with enough vector to reach muscle everywhere. That flood is what a body's innate immune system reads as an attack, and in three Elevidys patients, and now at least one HG302 patient, the reaction was severe enough to cause fatal organ failure, liver failure in the U.S. cases, ARDS in Shanghai. The FDA restricted Elevidys to ambulatory patients only in November 2025, after three deaths, and published its reasoning. HuidaGene took a year to say anything at all. Same failure mode, two disclosure timelines.
HuidaGene's read is that one patient reacted unpredictably to a high dose, not that the editing approach itself is unsound. Critics point instead to the missing data monitoring committee and the missing registry entry as the failure that was actually preventable. Both can be true. Beijing's new May 2026 framework for investigator-initiated trials makes adverse-event reporting mandatory; whether that requirement applies retroactively to HG302's roster is still unsettled, and the three boys' families must decide whether to continue before that question is resolved.
Sources
- STAT News (statnews.com)
- Bloomberg (bloomberg.com)
- CNN (cnn.com)
- The Standard (HK) (thestandard.com.hk)
- Tech Times (techtimes.com)
- BioPharma Dive (biopharmadive.com)